Clearmind Advances CMND-100 Trial After Positive DSMB Review

Event summary

  • Clearmind's Data Safety Monitoring Board (DSMB) recommended continuing the Phase I/IIa trial of CMND-100 for Alcohol Use Disorder (AUD).
  • The third cohort showed no serious adverse events, with CMND-100 well tolerated at current doses.
  • The trial will proceed to a fourth cohort with an increased dose of 160mg.
  • The multinational, multicenter study evaluates safety, tolerability, pharmacokinetics, and preliminary efficacy.

The big picture

Clearmind's progress in the CMND-100 trial underscores the growing interest in neuroplastogen-derived therapeutics for mental health disorders. The positive DSMB recommendation strengthens its position in a competitive landscape, where non-hallucinogenic alternatives are increasingly sought after. Success here could validate Clearmind’s approach and attract further investment in psychedelic-based pharmaceuticals.

What we're watching

Dose Escalation Impact
How the increased dose of CMND-100 will affect safety and efficacy outcomes in the next cohort.
Regulatory Pathway
Whether the positive DSMB recommendation accelerates FDA approval timelines for CMND-100.
Market Differentiation
The pace at which Clearmind can establish CMND-100 as a leading non-hallucinogenic treatment for AUD.

Related topics

Pharmaceuticals